For U.S. Healthcare Professionals
Start with OPSUMIT® (macitentan) to reduce the risks of disease progression and hospitalization for PAH1
In the treatment of pulmonary arterial hypertension (PAH, WHO Group I, Functional Class II-III)
Individual patient experience may vary.
*Source: IQVIA NPA TRx (Q1 2023-Q4 2023) and US claims data based on total prescriptions and refills from January 2023 to December 2023 and October 2022 to September 2023, demonstrating that OPSUMIT® is the #1 most-prescribed branded ERA therapy in PAH Nationwide.
HCP=healthcare professional;
PAH=pulmonary arterial hypertension;
PAH-CTD=PAH associated with connective tissue disease;
REPAIR=Right vEntricular remodeling in Pulmonary ArterIal hypeRtension;
SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve CliNical
Outcome;
WHO=World Health Organization.
References:
1. OPSUMIT® (macitentan) full Prescribing Information. Actelion Pharmaceuticals US, Inc.
2. Data on file (December 2023). Actelion Pharmaceuticals US, Inc. Based on Express Scripts Pharmacy Benefits Manager Claims Data (from January 2023 to December 2023), Optum Clinformatics Extended Data Mart (from October 2022 to September 2023), proprietary claims data (from November 2022 to October 2023), and IQVIA NPA TRx Data (January 2023 to December 2023).
To report suspected adverse reactions, contact Johnson & Johnson at 1-800-526-7736, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This site is intended for U.S.
healthcare professionals
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
By clicking on “Continue” below, you will leave OpsumitHCP.com and be directed to the Janssen CarePath site.
You are now leaving OpsumitHCP.com
By clicking on “Continue” below, you will leave OpsumitHCP.com and be directed to the site for iAssist registration.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
You are now leaving OpsumitHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.